Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Musa Tariq sold 116 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $149.56, for a total transaction of $17,348.96. Following the sale, the director owned 11,717 shares of the company’s stock, valued at approximately $1,752,394.52. This represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Friday, October 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $165.88, for a total transaction of $19,242.08.
- On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $175.00, for a total transaction of $20,300.00.
Guardant Health Stock Performance
Shares of NASDAQ:GH traded down $0.75 during midday trading on Tuesday, hitting $143.28. 1,960,154 shares of the company’s stock traded hands, compared to its average volume of 2,217,595. Guardant Health, Inc. has a twelve month low of $74.55 and a twelve month high of $191.05. The company has a market cap of $19.38 billion, a PE ratio of -38.93 and a beta of 1.67. The firm’s fifty day moving average price is $168.29 and its two-hundred day moving average price is $133.16.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analysts’ expectations of $350.72 million. The business’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.74) earnings per share. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.
Analysts Set New Price Targets
GH has been the topic of a number of analyst reports. BTIG Research lifted their price objective on shares of Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Stifel Nicolaus upped their target price on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, July 31st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $210.00 price target on shares of Guardant Health in a report on Friday, July 31st. Rothschild & Co Redburn assumed coverage on shares of Guardant Health in a research note on Tuesday, September 8th. They set a “buy” rating and a $203.00 price target on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research note on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $190.88.
Check Out Our Latest Report on GH
Hedge Funds Weigh In On Guardant Health
Institutional investors and hedge funds have recently made changes to their positions in the business. ABS Investment Management LLC bought a new stake in shares of Guardant Health in the second quarter worth $345,069,000. MCF Advisors LLC boosted its stake in Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after acquiring an additional 151 shares during the last quarter. NFSG Corp acquired a new position in Guardant Health during the 3rd quarter worth $33,000. Jacobi Capital Management LLC acquired a new position in Guardant Health during the 3rd quarter worth $35,000. Finally, Fulcrum Asset Management LLP bought a new stake in shares of Guardant Health in the 3rd quarter worth about $37,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Stories
- Five stocks we like better than Guardant Health
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
